Codexis

Codexis has engineered IVT enzymes to overcome the obstacles of producing high-quality mRNA at commercial scale. At Codexis, we strive to innovate sustainable processes and products, and discover and develop effective therapeutics – all to create a brighter future. Reimagine enzymes as enablers for efficient pharmaceutical manufacturing, sequencing and diagnostic applications, RNA manufacturing and more. Engineered enzymes can overcome current challenges, bottlenecks and enable new methods for product and process innovations. Engineered, high-quality biocatalysts can transform processes with enhanced activity and stability, leading to efficient and sustainable production of pharmaceuticals. The challenges associated with in vitro transcription (IVT) to manufacture large quantities of mRNA requires high performance enzymes that reduce impurities and produce capped, full-length mRNA. High-performing and specifically tailored for life science research needs, our enzyme products improve processivity, boost efficiency and withstand more challenging condition resulting in faster and more versatile workflows and better yields. We offer research and development partnership options to develop and deliver quality engineered enzyme solutions, providing a path to successful commercialization including screening, proof-of-concept, evolution, and options to scale-up and supply custom enzymes.